Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
Download media release - Whitchurch
Transcript
37 SANDIFORD DRIVE, 4TH FLOOR STOUFFVILLE, ONTARIO L4A 7X5 MAIN SWITCHBOARD: AUTOMATED LINES: FAX: 905-640-1900 905-895-2423 905-640-1910 905-895-5299 905-640-7957 MEDIA RELEASE For Immediate Release: January 15, 2008 Council Advances Approvals for Novopharm Pharmaceutical Expansion in Stouffville At their January 15 meeting, Town Council gave approval to Novopharm’s multi-million dollar expansion project. The Conditional Building Permit will allow the company to immediately start construction of a new Research and Development (R&D) facility at its Stouffville site and to fast track the project. “We are very proud of our relationship with Novopharm and very excited about this high tech project in our community,” explained Mayor Wayne Emmerson. “Town Council has agreed to expedite the local approvals process for this project,” he added. Located in the Community of Stouffville, the R&D facility will include state-of-the-art laboratory facilities and will focus on innovative research and development of generic pharmaceutical products including “modified drug release” technology. The new products will be available for the Canadian, American and European markets. Many of these products will also be manufactured in the company’s Stouffville facility, increasing its output to 7 billion tablets and capsules annually. “We are thrilled to continue our expansion in Stouffville and are proud of our demonstrated commitment to the pharmaceutical industry and to drug research in Canada,” stated Novopharm President and CEO Allan Oberman. “Stouffville provides an ideal location for our company with extensive expansion opportunities and a location that is accessible for our employees,” he added. Novopharm is owned by Teva Pharmaceutical Industries, an international pharmaceutical company specializing in generic drug research and manufacturing. The company has an existing manufacturing complex in the Community of Stouffville, employing 300. The new investment will see the creation of an additional 20,000 square feet (2,000 sq. m) of R & D laboratories and offices. It is expected that this centre will employ 70-80 scientists and technicians when it opens later this year. Construction of the site works is underway, with building construction commencing immediately. The company is also working with the Town on an overall site plan for the complex, including road re-alignments and widenings to improve access and traffic flow in the area. -30For further information, contact: Mayor Wayne Emmerson Town of Whitchurch-Stouffville 905-640-1910, ext. 227 [email protected] David J. Cash, Chief Administrative Officer Town of Whitchurch-Stouffville 905-640-1910, ext. 237 [email protected] Stephanie Brooks Novopharm / Relevents Inc. 416-282-7955 [email protected]
